Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416641 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL29846085 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL29520571 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL30946745 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL30946746 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL30946743 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL30416902 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL30946744 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL30946742 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL19000752 | 1.00 | TDP1 (0.47) | TDP1MEN1KMT2ATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000581-B2 | Therapeutic and imaging compositions and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170179362-A1 | THERMOELECTRIC CONVERSION ELEMENT, n-TYPE THERMOELECTRIC CONVERSION LAYER, AND COMPOSITION FOR FORMING n-TYPE THERMOELECTRIC CONVERSION LAYER | FUJIFILM CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20160083485-A1 | THERAPEUTIC AND IMAGING COMPOSITIONS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000581-B2 | Therapeutic and imaging compositions and uses thereof | NPC1, NPC1L1, GBA1 | TDP1 3112/4885MEN1 764/4885KMT2A 3408/4885 |
| US-20160083485-A1 | THERAPEUTIC AND IMAGING COMPOSITIONS AND USES THEREOF | NPC1, NPC1L1, GBA1 | TDP1 3112/4885MEN1 764/4885KMT2A 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.